Associations between eNOS polymorphisms and susceptibility to Behcet's disease: a meta-analysis.

Authors: Lee, YH  Song, GG 
Citation: Lee YH and Song GG, J Eur Acad Dermatol Venereol. 2012 Oct;26(10):1266-71. doi: 10.1111/j.1468-3083.2011.04280.x. Epub 2011 Sep 29.
Pubmed: (View Article at PubMed) PMID:21957880
DOI: Full-text: DOI:10.1111/j.1468-3083.2011.04280.x

OBJECTIVE: To determine whether endothelial nitric oxide synthase (eNOS) polymorphisms confer susceptibility to Behcet's disease (BD). METHODS: A meta-analysis was conducted on the associations between the G894T and 4b/a polymorphisms of eNOS and BD using: (i) the allele contrast, (ii) the recessive model, (iii) the dominant model and (iv) the additive model. RESULTS: A total of eight studies, which included 841 cases and 866 controls, were included in the meta-analysis. Meta-analysis of the G894T polymorphism revealed no association with BD in all study subjects or in Turkish and Asian populations. However, one Tunisian study of the T allele showed a significant association with BD (OR = 0.707, 95% CI = 0.510-0.980, P = 0.038), but the OR of the T allele among Tunisians was lower, whereas it was higher in Europeans (OR = 2.129, 95% CI = 1.407-3.220, P = 0.0003). Meta-analysis showed no association between BD and the 4b/a polymorphism in all study subjects. Stratification by ethnicity indicated no significant association between the a allele of the 4b/a polymorphism and BD in Turkish and Asian populations. CONCLUSIONS: This meta-analysis shows that the eNOS G894T and the 4b/a polymorphisms are not associated with BD in the Turkish and Asian populations. These data suggest that the G894T and the 4b/a polymorphisms may not confer susceptibility to BD in the Turkish and Asian populations.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 7775050
Created: 2013-12-31
Species: All species
Last Modified: 2013-12-31
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.